Also known as Dihexa (Tablets), pnb-0408, angiotensin iv analogue, hgf/c-met modulator · Wikipedia
Dihexa (PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an orally bioavailable, blood-brain-barrier-permeable small molecule derived from angiotensin IV, developed at Washington State University by the Wright/Harding group. It is sold by peptide vendors as oral tablets and injectable solutions but is technically a non-peptidic small molecule because its hexanoic-acid and 6-aminohexanoic-amide linkers are not standard amino acids. Dihexa is a hepatocyte growth factor (HGF) / c-Met positive allosteric modulator with reported sub-nanomolar potency at synaptogenesis assays. All efficacy data are preclinical (rodent scopolamine and aged-rat memory models); no human clinical trials have been published.
—
best
price
—
per
mg
—
vendors
tracked
Preclinical
stage
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
Dihexa functions as a hepatocyte growth factor (HGF) / c-Met receptor positive modulator. It binds with high affinity to HGF and augments c-Met phosphorylation at sub-threshold HGF concentrations, mimicking endogenous HGF signaling at sub-nanomolar potency (Benoist et al.
Pharmacokinetic properties
Half-life
Prolonged: ~12.7 days after IV and ~8.8 days after IP in rodent studies; human PK not published
Routes
oral · subcutaneous · intranasal
Bioavailability
Designed for oral bioavailability and BBB penetration via lipophilic modifications. Rodent oral dosing at 2 mg/kg/day reverses scopolamine-induced cognitive deficits, confirming meaningful CNS exposure after PO administration.
Amino-acid sequence
N-hexanoyl-Tyr-Ile-6-aminohexanoic amide (AngIV analogue)
Use & research dosing
Research framing only. There is no human dose-finding trial. Self-experimentation reports in nootropic communities cite oral or sublingual doses of 8-45 mg per day, often divided, with courses lasting weeks to months. These figures are back-extrapolated from rodent oral dosing of approximately 2 mg/kg/day used in scopolamine reversal studies and have no human safety validation. Oral tablet absorption and brain penetration in humans have not been characterized. The compound's long rodent terminal half-life (~9-13 days IV/IP) suggests accumulation potential with chronic dosing; appropriate dose intervals in humans are unknown.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Dihexa was developed at Washington State University as a clinical candidate for Alzheimer's disease but has not progressed into registered human trials. The HGF/c-Met pathway is a double-edged target: it drives synaptogenesis and tissue repair but is also a validated oncogenic axis (c-Met is targeted by approved cancer drugs such as crizotinib), so chronic off-label use in humans carries a theoretical proliferative-risk concern. The oral tablet form is sold despite uncharacterized human absorption; the molecule is structurally a small-molecule peptidomimetic, not a true peptide.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
low
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.